The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ODYY | +10.18% | -82.18% | -29.16% | -88% |
| S&P | +14.77% | +87.2% | +13.35% | +184% |
Odyssey Health, Inc. is a medical device technology and asset acquisition company. It engages in the development and acquisition of medical devices and health related technologies. The firm also owns technology and the marketing and distribution rights to CardioMap, which is intended to be an advanced technology for early non-invasive testing for heart disease. The company was founded in March 2014 and is headquartered in Las Vegas, NV.
No news articles found for Odyssey Health.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $7.42M | 309.5% |
| Market Cap / Employee | $3.71M | 0.0% |
| Employees | 2 | -50.0% |
| Net Income | -$483.45K | 52.6% |
| EBITDA | -$303.19K | 47.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $25.59K | -52.5% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $1.97M | 1.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -498.17% | -207.2% |
| Return On Invested Capital | 186.02% | -216.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$284.00K | -14.3% |
| Operating Free Cash Flow | -$284.00K | -14.3% |
| Metric | Q1 2024 | Q2 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 0.96 | 0.42 | - | ||
| Price to Book | -0.33 | -0.09 | -0.31 | -1.03 | -549.41% |
| Price to Tangible Book Value | -0.33 | -0.09 | -0.31 | -1.03 | -549.41% |
| Enterprise Value to EBITDA | -26.88 | -20.39 | -26.16 | -32.41 | 386.30% |
| Return on Equity | 640.4% | 1070.2% | -1342.7% | -2418.5% | - |
| Total Debt | $1.97M | $1.98M | $1.98M | $1.97M | 1.05% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
